Tofacitinib (Xeljanz®, Pfizer) was approved by the USFDA as a JAK3-selective suppressor for rheumatoid arthritis (RA) therapy in year 2012 and recently approved to treat Ulcerative Colitis (112). The gene discussed is JAK3; the disease is rheumatoid arthritis.